{"id":821109,"date":"2025-03-04T07:06:22","date_gmt":"2025-03-04T12:06:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/"},"modified":"2025-03-04T07:06:22","modified_gmt":"2025-03-04T12:06:22","slug":"natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/","title":{"rendered":"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD"},"content":{"rendered":"

<\/p>\n

Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD<\/b><\/p>\n

AUSTIN, Texas–(BUSINESS WIRE<\/a>)–Natera, Inc.<\/a> (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA (ctDNA). This builds on Natera\u2019s extensive intellectual property estate, including a strong portfolio of molecular residual disease testing (MRD) patents for whole exome and whole genome sequencing.\n<\/p>\n

\nU.S. patent No. 12,203,142 relates to certain methods of preparation useful for tumor-informed ctDNA monitoring using whole exome or whole genome sequencing. The patent describes various modes of target enrichment in the plasma, including both multiplex polymerase chain reaction PCR and capture by hybridization.\n<\/p>\n

\nNatera has more than 110 patents relating to cell-free DNA analysis for oncology testing, including 23 patents obtained in 2024.\n<\/p>\n

About Natera<\/b><\/p>\n

\nNatera\u2122 is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women\u2019s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera\u2019s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera\u2019s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera\u2019s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to the scope of protection we establish and maintain for our intellectual property or other proprietary rights. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera\u2019s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com\/investors<\/a> and www.sec.gov<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250303806272\/en\/<\/a><\/span><\/p>\n

\nInvestor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
\n<\/a>
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Texas<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Genetics General Health Research Science Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA (ctDNA). This builds on Natera\u2019s extensive intellectual property estate, including a strong portfolio of molecular residual disease testing (MRD) patents for whole exome and whole genome sequencing. U.S. patent No. 12,203,142 relates to certain methods of preparation useful for tumor-informed ctDNA monitoring using whole exome or whole genome sequencing. The patent describes various modes of target enrichment in the plasma, including both multiplex polymerase chain reaction PCR and capture … <\/p>\n

Continue reading “Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-821109","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNatera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA (ctDNA). This builds on Natera\u2019s extensive intellectual property estate, including a strong portfolio of molecular residual disease testing (MRD) patents for whole exome and whole genome sequencing. U.S. patent No. 12,203,142 relates to certain methods of preparation useful for tumor-informed ctDNA monitoring using whole exome or whole genome sequencing. The patent describes various modes of target enrichment in the plasma, including both multiplex polymerase chain reaction PCR and capture … Continue reading "Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-04T12:06:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250303806272r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD\",\"datePublished\":\"2025-03-04T12:06:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\\\/\"},\"wordCount\":451,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250303806272r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\\\/\",\"name\":\"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250303806272r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-03-04T12:06:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250303806272r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250303806272r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/","og_locale":"en_US","og_type":"article","og_title":"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD - Market Newsdesk","og_description":"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA (ctDNA). This builds on Natera\u2019s extensive intellectual property estate, including a strong portfolio of molecular residual disease testing (MRD) patents for whole exome and whole genome sequencing. U.S. patent No. 12,203,142 relates to certain methods of preparation useful for tumor-informed ctDNA monitoring using whole exome or whole genome sequencing. The patent describes various modes of target enrichment in the plasma, including both multiplex polymerase chain reaction PCR and capture … Continue reading \"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-04T12:06:22+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250303806272r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD","datePublished":"2025-03-04T12:06:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/"},"wordCount":451,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250303806272r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/","name":"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250303806272r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-03-04T12:06:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250303806272r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250303806272r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=821109"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821109\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=821109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=821109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=821109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}